Assessment of abuse liability of pheniramine among opioid-dependent human subjects

References

• Basu, D., Malhotra, A., & Varma, V. (1990). Buprenorphine dependence: a new addiction in India. Disabilities and Impairments, 3, 142–146.
   Google Scholar
• Basu, D., Mattoo, S. S. K., Malhotra, A., Gupta, N., & Malhotra, R. (2003). A longitudinal study of male buprenorphine addicts attending an addiction clinic in India. Addiction, 95, 1363–1372.
   Google Scholar
• Beitz, R., Doren, M., Knopf, H., & Melchert, H. U. (2004). Over-the-counter self medication in Germany. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz, 47, 1043–1050.
   PubMedGoogle Scholar
• Buckley, N. A., Whyte, I. M., Dawson, A. H., & Cruickshank, D. A. (1994). Pheniramine—A much abused drug. Medical Journal of Australia, 160, 188–192.
   PubMed Web of Science ®Google Scholar
• Center for Disease Control and Prevention. (2005). Unintentional deaths from drug poisoning by urbanization of area: New Mexico, 1994–2003. Morbidity and Mortality Weekly Report, 54, 870–873.
   PubMedGoogle Scholar
• Chowdhury, A. & Chowdhury, S. (1990). Buprenorphine abuse: Report from India. British Journal of Addiction, 85, 1349–1350.
   PubMedGoogle Scholar
• Chowdhry, A. N. & Chowdhry, S. (2006) Buprenorphine abuse: report from India. Addiciton, 85, 1349–1350.
   Google Scholar
• Cole, J., Hecht-Orzack, M., Beake, B., Bird, M., & Bar Ttal, Y. (1982). Assessment of the abuse liability of buspirone in recreational sedative users. Journal of Clinical Psychiatry, 43, 69–74.
   PubMed Web of Science ®Google Scholar
• Craig, V. & Showalter, M. D. (1980). Abuse of pentazocine and tripelennamine. Journal of the American Medical Association, 244(11), 1224–1225.
   Web of Science ®Google Scholar
• de Wit, H. & Griffiths, R. (1991). Testing the abuse liability of anxiolytics and hypnotic drugs in humans. Drug and Alcohol Dependence, 28, 83–111.
   PubMed Web of Science ®Google Scholar
• Dollery, C. ( ed). (1991a) Pheniramine. In Therapeutic Drugs (pp. P81–P83). London: Churchill Livingstone.
   Google Scholar
• Dollery, C. ( ed). (1991b) Lorazepam. In Therapeutics Drugs (pp. L98–L101). London: Churchille Livingstone.
   Google Scholar
• Estelle, F. & Simons, R. (2004). Advances in H1-antihistamines. New England Journal of Medicine, 351, 2203–2217.
   PubMed Web of Science ®Google Scholar
• Evans, S., Fuderburk, F., & Griffiths, R. (1990). Zolpidem and triazolam in humans: behavioral and subjective effects and abuse liability. Journal of Pharmacology and Experimental Therapeutics, 225, 1246–1255.
   Google Scholar
• Fraser, H. F. & Jasinski, D. R. (1977). The assessment of the abuse potentiality of sedative/hypnotics (depressants): methods used in animals and man. In W. R. Martin ( Ed.) Drug addiction I: Morphine, sedative/hypnotic and alcohol dependence ( pp. 589–612). New York: Springer-Verlag.
   Google Scholar
• Fraser, H., Van Horlyn, G., Martin, W., Walbach, A., & Isbell, H. (1961). Methods of assessing addiction liability. Journal of Pharmacology and Experimental Therapeutics, 133, 371–374.
   PubMed Web of Science ®Google Scholar
• Griffiths, R., Bigelow, G., & Ator, N. A. (2003). Principles of initial experimental drug abuse liability assessment in humans. Drug and Alcohol Dependence, 70, S41–S54.
   PubMed Web of Science ®Google Scholar
• Griffiths, R. R., Bigelow, G. E., & Liebson, I. A. (1983). Differential effects of diazepam and pentobarbital on mood and behavior. Archieves of General Psychiatry, 40, 865–873.
   PubMed Web of Science ®Google Scholar
• Griffiths, R. R., McLeod, D. R., Bigelow, G. E., Liebson, I. A., & Roache, J. D. (1984a). Relative abuse liability of diazepam and oxazepam: behavioral and subjective dose effects. Psychopharmacology, 84, 147–154.
   PubMed Web of Science ®Google Scholar
• Griffiths, R. R., McLeod, D. R., Bigelow, G. E., Liebson, I. A., Roache, J. D., & Nowowieski, P. (1984b). Comparison of diazepam and oxazepam: preference, liking and extent of abuse. Journal of Pharmacology and Experimental Therapeutics, 229, 501–508.
   PubMed Web of Science ®Google Scholar
• Haertzen, C. A. (1966). Development of scales based on patterns of drug effects, using the Addiction Research Center Inventory (ARCI). Psychological Reports, 18, 163–194.
   PubMed Web of Science ®Google Scholar
• Haertzen, C. A. (1974). An overview of addiction research center inventory scales (ARCI): An appendix and manual of scales (DHEW Publication No. ADM 74–92). Washington, DC: U.S. Government Printing Office.
   Google Scholar
• Haertzen, C., Hill, H., & Bellerille, R. (1963). Development of the Addiction Research Center Inventory (ARCI): selection of items that is sensitive to effects of various drugs. Psychopharmacology, 4, 155–166.
   PubMed Web of Science ®Google Scholar
• Hughes, G. F., McElnay, J. C., Hughes, C. M., & McKenna, P. (1999). Abuse/misuse of non-prescription drugs. Pharmacy World & Science, 21, 251–255.
   PubMed Web of Science ®Google Scholar
• Jaffe, J. H., Ciraulo, D. A., Nies, A., Dixon, R. B., & Monroe, L. L. (1983). Abuse potential of halazepam and of diazepam in patients recently treated for acute alcohol withdrawal. Clinical Pharmacology & Therapeutics, 34, 623–630.
   PubMed Web of Science ®Google Scholar
• Jain, R. ( Ed). (1996). Analytical method in drugs of abuse in body fluids: a manual for health professionals. New Delhi: De addiction Centre, AIIMS.
   Google Scholar
• Jasinski, D. R., Haertzen, C. A., Henningfield, J. E., Johnson, R. E., Makhzoumi, H. M., & Miyasato, K. (1982). Progress Report of the NIDA Addiction Research Center. In L. S. Harris ( Ed.) Problems of drug dependence, 1981 (National Institute on Drug Abuse Research Monograph 41) ( pp. 45–52). Washington, DC: U.S. Government Printing Office.
   Google Scholar
• Jasinski, D. R., Henningfield, J. E., Hickey, J. E., & Johnson, R. E. (1983). Progress report of the National Institute on Drug Abuse Addiction Research Center, 1982. In L. S. Harris ( Ed.) Problems of drug dependence, 1982 (National Institute on Drug Abuse Research Monograph 43) ( pp. 92–98). Washington, DC: U.S. Government Printing Office.
   Google Scholar
• Jasinski, D. R., Martin, W. R., & Sapira, J. D., (1968). Antagonism of the subjective, behavioral, pupillary, and respiratory depressant effects of cyclazocine by naloxone. Clinical Pharmacology and Therapeutics, 9(2), 215–222.
   PubMed Web of Science ®Google Scholar
• Jerome, J. H., Roger, B., Ilana, C., Malcolm, C., Farrukh, A., Arnol, S., & Roger, M. E. (2004). A postmarketing study of relative abuse liability of hypnotic sedative drugs. Addiction, 99, 165–173.
   PubMed Web of Science ®Google Scholar
• Kumar, V. & Singh, B. (1996). Reasons behind increasing buprenorphine abuse. Indian Journal of Psychiatry, 38(suppl), 82.
   Google Scholar
• Lal, R. (1991). Buprenorphine dependence: analysis of seven cases. Indian Journal of Psychiatry, 33, 62–65.
   Google Scholar
• McLeod, D. R., & Griffiths, R. R., (1983). Human progressive-ratio performance: maintenance by pentobarbital. Psychopharmacology, 79, 4–9.
   PubMed Web of Science ®Google Scholar
• McNair, D. M., Lorr, M., & Droppleman, L. F. (1992). Revised Manual for the Profile of Mood States. San Diego, CA: Educational and Industrial Testing Service.
   Google Scholar
• National Survey on Drug Use and Health. (2004). Characteristics of primary prescription and OTC treatment admissions: 2002. Washington, DC: Office of Applied Studies, Substance Abuse and Mental Health Services Administration.
   Google Scholar
• Pal, H., Kumar, R., Bhushan, S., & Berry, N. (2005). Psychaitric co-morbidity associated with pheniramine abuse and dependence. Indian Journal of Psychiatry, 47, 60–62.
   Google Scholar
• Paton, C. (2002). Benzodiazepines and disinhibition: a review. The Psychiatrist, 26, 460–462.
   Google Scholar
• Pragst, F., Herre, S., & Bakdash, A. (2006). Poisonings with diphenhydramine: a survey of 68 clinical and 55 death cases. Forensic Science International, 161, 189–197.
   PubMed Web of Science ®Google Scholar
• Roache, J. & Griffiths, R. (1987). Lorazepam and meprobamate dose effects in humans: behavioral effects and abuse liability. The Journal of Pharmacology and Experimental Therapeutics, 243, 978–988.
   PubMed Web of Science ®Google Scholar
• Sharma, Y. & Mattoo, S. (1999). Buprenorphine abuse in India: an update. Indian Journal of Psychiatry, 41, 154–159.
   PubMedGoogle Scholar
• Singh, R., Mattoo, S., Malhotra, A., & Varma, V. (1992). Cases of buprenorphine abuse in India. Acta Psychiatrica Scandinavica, 86, 46–48.
   PubMed Web of Science ®Google Scholar
• Sleath, B., Rubin, R.H. & Campbell, W., Gwyther, L., & Clark, T. (2001). Physician-patient communication about over-the-counter medications. Social Science & Medicine, 53, 357–369.
   PubMed Web of Science ®Google Scholar
• Suresh, M. ( personal communication). Rapid situation assessment on injecting drug use in Chennai south India. UNESCO DAPPA.
   Google Scholar
• Umesh Babu, S. & Chaturvedi, S. (1995). Changing patterns of opiate abuse with a focus on buprenorphine (abstract). Indian Journal of Psychiatry, 37(suppl), 23.
   PubMedGoogle Scholar
• WHO. (1988). Benzodiazepines and therapeutic counselling report from a WHO collaborating study. New York: Springer Verlag.
   Google Scholar